14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and other movement disordersInterim data from the ongoing EPITOME trial1 showed that 45.7% of stroke survivors with paresis developed post-stroke spasticity within 1 year<1% of stroke survivors receive BoNT-A treatment for spasticity in routine practice2 PARIS, FRANCE, 14 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of 14 across mult ...